Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CoFactor (Biokeys Pharmaceuticals).

K L Seley1

  • 1Georgia Institute of Technology, School of Chemistry and Biochemistry, Boggs Building, Atlanta, GA 30332-0400, USA. seley@chem-mail.chemistry.gatech.edu

Idrugs : the Investigational Drugs Journal
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective transport of a new class of purine antimetabolites by the protozoan parasite Trypanosoma brucei.

Nucleosides, nucleotides & nucleic acids·2004
Same author

Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues.

Antiviral chemistry & chemotherapy·2002
Same author

"Fleximers". Design and synthesis of two novel split nucleosides.

Organic letters·2001
Same author

Tezacitabine Hoechst Marion Roussel.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Synthesis and antitumor activity of thieno-separated tricyclic purines.

Journal of medicinal chemistry·2000
Same author

Carbocyclic 5'-noruridine.

Nucleosides, nucleotides & nucleic acids·2000

CoFactor, a thymidylate synthase inhibitor, enhances 5-fluorouracil cancer therapy. Pharmacogenomic studies aim to identify patients who will best respond to this combination treatment.

Area of Science:

  • Oncology
  • Pharmacogenomics

Background:

  • CoFactor (methylenetetrahydrofolate) is a thymidylate synthase inhibitor developed to enhance 5-fluorouracil (5-FU) cancer treatment.
  • Phase I/II trials of CoFactor in combination with 5-FU were completed, with Phase III trials planned.

Purpose of the Study:

  • To conduct a pharmacogenomic study of CoFactor to identify patients likely to respond to 5-FU/CoFactor therapy.
  • To analyze tissue samples from patients treated in Phase I/II trials to understand treatment responses.

Main Methods:

  • Retrospective analysis of paraffin-embedded tissue samples using RT-PCR.
  • Genomic screening to predict patient response to 5-FU/CoFactor therapy.

Main Results:

  • CoFactor demonstrated 100-fold greater promotion of thymidylate synthase inhibition compared to leucovorin.

Related Experiment Videos

  • Phase I/II trials showed partial responses in 21-55% of patients with colorectal, pancreas, stomach, gallbladder, and breast cancer.
  • CoFactor exhibited milder toxicity than 5-FU or 5-FU/leucovorin.

    • Conclusions:

    • CoFactor shows promise in enhancing 5-FU efficacy across various cancer types.
    • Pharmacogenomic screening may optimize patient selection for 5-FU/CoFactor therapy.
    • Further research is warranted to fully elucidate CoFactor's role in cancer treatment.